Drug-related predictors of schizophrenia readmission

Slides:



Advertisements
Similar presentations
Treating Schizophrenia in Low And Middle Income (LAMI) Countries: Challenges and opportunities Treating Schizophrenia in Low And Middle Income (LAMI) Countries:
Advertisements

Context and Overview of Recommended Actions to Reduce Psychiatric Readmissions Michael Trangle, MD Associate Medical Director, Behavioral Health Division.
Session 1: Overview of the Guidelines and Comorbidity
Poor Bipolar Outcome The Effect of Substance Abuse On Bipolar Disorder Phillip Long M.D.
Delay from Testing HIV Positive until First HIV Care for Drug Users: Adverse Consequences and Possible Solutions Barbara J Turner MD, MSEd* John Fleishman.
Module 4: Interaction of. Objectives To be aware of the possible reasons why dual diagnosis occurs To be aware of the specific effects of substances on.
Facts In 2008, an estimated 20.1 million Americans aged 12 or older were current (past-month) illicit drug users. (8.0% of the population) million.
Dr. Elaine Dunnea, Dr. Maura Dugganb, Dr. Julie O’Mahonyc
Marijuana and Teenage Psychosis David Ruffino Student Nurse. PPC Term Five.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December 2007.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May-June 2007.
Journal Club Alcohol and Health: Current Evidence September–October 2004.
COMORBIDITY IN ADDICTION AND OTHER MENTAL ILLNESSES The Chiromo Lane Medical Centre (CLMC) Approach.
Chapter 2 The Problem of Dual Diagnosis. Dual Diagnosis and Comorbidity Dual diagnosis – Describes individuals who meet diagnostic criteria for a mental.
® Introduction Mental Health Predictors of Pain and Function in Patients with Chronic Low Back Pain Olivia D. Lara, K. Ashok Kumar MD FRCS Sandra Burge,
Wei Hao, MD. Mental Health Institute WHO Collaborating Center for Drug Abuse and Health Central South University Prevalence Rates and Related Factors of.
Audrey J. Brooks, PhD University of Arizona CA-AZ node.
Priority Groups for Choose Life Overview. Children (especially looked after children): Deaths of children aged 0-14: < 5 per year (GROS) Highest in males.
SLIDE 1 of 34 IS THERE A CAUSAL RELATIONSHIP BETWEEN SUBSTANCE ABUSE AND PSYCHIATRIC ILLNESS? Dr Martin Frisher Department of Medicines Management Keele.
Introduction History of Childhood Abuse and Recovery of Neurocognition during Inpatient Psychiatric Rehabilitation: 18-Month Longitudinal Study Kee-Hong.
The relationship between substance abuse treatment and self-reported outcomes among offenders with mental health problems and substance use problems Natalie.
The Competency Assessment Brian P. Skop, M.D. Forensic Psychiatric Consultant to University Health System Associate Clinical Professor of Psychiatry University.
Obtaining housing associated with achieving abstinence after detoxification in adults with addiction Tae Woo Park, Christine Maynié-François, Richard Saitz.
Specific Aim 1: Determine the impact of psychiatric disorders on the hospital length of stay (LOS) in pediatric patients diagnosed with SCD admitted for.
APPLIED PSYCHOLOGY LABORATORY East Tennessee State University Johnson City, Tennessee INTRODUCTION CONTACT:
Changing Attitudes toward Marijuana How has marijuana changed from 1990 to 2015?
Substance Abuse, Medication Adherence, and Criminality among Mentally Ill Parolees David Farabee & Sylvia Sanchez UCLA Integrated Substance Abuse Programs.
DRUGS OF ABUSE Reynaldo J. Lesaca, M.D. Reynaldo J. Lesaca, M.D.
Terms & Definitions Samhsa’s Co-Occurring Center for Excellence COCE.
LENGTH OF FIRST HOSPITALIZATION AND OTHER PREDICTORS FOR RE-HOSPITALIZATION IN PSYCHOSES Jouko Miettunen, PhD Department of Psychiatry University of Oulu,
RISK FACTORS FOR REHOSPITALIZATION OF PATIENTS WITH MENTAL DISORDERS A CASE CONTROL STUDY Margaret Eliphy Nkangala, Bsc Health Science Education, Malawi.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
Prepared by: Using discrete event simulation to evaluate the cost-effectiveness of antipsychotics Pharmerit BV Marten Meesweg AV Rotterdam The.
Zach Walsh University of British Columbia This study examined the use of cannabis as a substitute for alcohol and other psychoactive.
Health care trajectories and medication consumption of substance users in treatment : linking TDI and IMA databases (Belgium) De Ridder Karin, Antoine.
Brain diseases: Substance abuse and co-occurring disorders Mark Publicker, MD FASAM.
Management of Substance Use Disorder Module P: Addiction-Focused Pharmacotherapy.
Cannabis and Schizophrenia. Major Constituents of Cannabis The two major substances found in cannabis include tetrahydrocannabinol (THC) and cannibidiol.
Randomized Controlled CTN Trial of OROS-MPH + CBT in Adolescents with ADHD and Substance Use Disorders Paula Riggs, M.D., Theresa Winhusen, PhD., Jeff.
Medication Adherence and Substance Abuse Predict 18-Month Recidivism among Mental Health Jail Diversion Program Clients Elizabeth N. Burris 1, Evan M.
A comprehensive evaluation of post- mortem findings and psychiatric case records of individuals who died by probable suicide. A van Laar, J Kielty, M Davoren,
Biomedical Research Centre for Mental Health and Dementia Unit at South London and Maudsley NHS Foundation Trust the Institute of Psychiatry, King’s College.
ANOREXIA/BULIMIA Young adolescent women, 90% female Risk groups – higher social classes, models, athletes, dancers, students, hx sexual abuse Comorbid.
The Royal College of Emergency Medicine Mental Health in the ED Clinical Audit National findings The Royal College of Emergency Medicine Clinical.
Background and Objectives
The study of the causes of diseases
Psychological treatment of Schizophrenia
for Overall Prognosis Workshop Cochrane Colloquium, Seoul
C Wilson, KM Rhodes, RA Payne
Modelling Madness Susan Totterdell.
COMORBIDITY IN ADDICTION AND OTHER MENTAL ILLNESSES
US Census Data Ortman, Jennifer M., Victoria A. Velkoff, and Howard Hogan. An Aging Nation: The Older Population in the United States, Current Population.
Drug addiction: Therapeutic problems in everyday clinical practice
CRISIS RESOLUTION / HOME TREATMENT - DEFINITION
Therapeutic relationships with multiple professionals in community mental healthcare Jocelyn Catty, Sarah White, Sarah Clement, Naomi Cowan, Gemma Ellis,
Lancet. 2017 Aug 5;390(10094): doi: /S (17) Epub 2017 May 25.
A systematic review of the relationship between substance abuse and psychotropic medication adherence: opportunities to improve outcomes for patients with.
Predicting offending after residential rehabilitation
Youth homelessness in Denmark Trends, profiles and family background
A2 unit 4 Clinical Psychology
Bidirectional Association Between Homelessness and Incarceration Among Veterans Participating in HUD-VASH Dennis Culhane, PhD.
A comparison between North and South of Europe
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Schizophrenia Care in the Community for Adults
ADDICTION
Beaver County Single Point of Accountability
Results: Specific Aim 2 (cont.)
Psychiatric comorbidities in adult survivors of major trauma:
Substance Use Prevention for Young Adults and Higher Education
Gender Issues and Addiction
Presentation transcript:

Drug-related predictors of schizophrenia readmission

Patients with schizophrenia and Sud have a severe course of illness Compared to patients with schizophrenia only, patients with comorbid SUD have: more positive symptoms and increased rates of relapse. poorer medication compliance, health and self-care in general. Previous studies have compared users and non-users, primarily regarding cannabis: Cannabis users have a higher risk of schizophrenia relapse compared to non-users or former users. We lack information about the role of specific substances from studies comparing substance abuse of different types of substances. Wade et al (2006) Br J Psychiatry; Margolese et al (2004) Schzophr Res.

Drug-induced psychotic symptoms Positive symptoms in schizophrenia are mediated by enhanced dopamine neurotransmission. Common to all addictive substances is their ability to increase synaptic dopamine concentrations in the striatum. A wide range of substances (e.g. cannabis, amphetamine, alcohol, cocaine) have been related to substance-induced psychotic symptoms: Cannabinoids and amphetamine can induce transient psychotic symptoms in HV and exacerbate psychosis in individuals with a psychotic disorder. Cocaine use can induce transient psychotic symptoms and behavioral symptoms, and possibly also psychosis. Howes et al (2012) Arch Gen Psychiatry; Alharbi & el-guebaly (2016) Addict Disord Their Treat; D’souza et al (2009) Eur Arch Psychiatry Clin Neuro; Roncero et al (2014) Subst Abus.

Do specific drugs increase risk of schizophrenia readmission? In summary: Patients suffering from schizophrenia and SUD have a worse prognosis, including more positive symptoms and increased risk of relapse. Different types of drugs can induce and exacerbate psychotic symptoms. Despite this, we have limited knowledge of the role of specific substances in readmission for schizophrenia among individuals suffering from comorbid SUD. AIM: Examine whether specific drugs increase risk of schizophrenia readmission.

A record-linkage study (N=634) A record-linkage study was used to examine drug-related predictors of readmission to mental health treatment for schizophrenia (F20), using two registers: The Registry of Drug Abusers Undergoing Treatment. The Danish Central Psychiatric Research Register. Cohort consisted of 634 patients with a history of schizophrenia, who were admitted to DUD treatment between 2000 and 2006 - and tracked in the psychiatric register until 2013. By looking at patients in DUD treatment we were able to examine effects of a range of substances incl. opioids, cannabis, amphetamine, alcohol, benzos, cocaine, and MDMA.  

analysis Outcome: Readmission for schizophrenia i.e. new treatment episode with a primary diagnosis of schizophrenia (F20), including emergency, outpatient, and inpatient settings. Univariate and multivariate time-to-event regression analyses were used to examine associations, using the Fine and Gray method. We included a broad range of variables: Background: Age, Gender, Ethnicity, Living by independent means, Living with children under 25, Single, More than mandatory education, Active, Previous offences. Psychiatric: Time since last psychiatric contact, Psychiatric inpatient past year, Psychiatric emergency services past year. Substance: Opioids, Cannabis, Amphetamine, Alcohol, Benzos, Cocaine, MDMA.

DRUG-RELATED findings Readmission for schizophrenia: 79% were readmitted, and 7% died without readmission. Reported substance use (DUD treatment): opioids (50%), cannabis (45%), amphetamine (21%), alcohol (21%), benzos (18%), cocaine (16%), MDMA (3%). UNIVARIATE ANALYSIS Use of amphetamine at baseline was associated with elevated risk of readmission for schizophrenia (p = 0.015). Being single (p = 0.036), and past year psychiatric emergency room (p < 0.000) and inpatient (p < 0.000) visits were associated with elevated risk of readmission. Living by independent means (p = 0.008), living with children (p = 0.005) and time since last psychiatric contact (p < 0.000) were associated with lower risk of readmission. The majority of patients were males (79.8%) and the mean age was 34.7 years.

DRUG-RELATED findings MULTIVARIATE ANALYSIS* Use of amphetamine (p = 0.014) and cannabis (p = 0.030) at baseline were associated with elevated risk of readmission for schizophrenia. Past year psychiatric inpatient visit (p < 0.001) was associated with elevated risk of readmission for schizophrenia. No associations with cocaine, opioids, alcohol, benzos and MDMA in the univariate or multivariate analyses. *Only variables that were significant in the univariate analysis were subjected to multivariate analysis, except substance use variables which were included irrespectively. The majority of patients were males (79.8%) and the mean age was 34.7 years.

Amphetamine use increases risk: Potential explanations Our finding is in line with previous studies showing that: Amphetamine can induce transient psychotic symptoms in HV and exacerbate psychosis in individuals with a psychotic disorder. Why amphetamine, and not e.g. cocaine? – Due to different mechanisms of action? Cocaine and amphetamine both work by inhibiting dopamine reuptake. Amphetamine works through additional mechanisms that elevate presynaptic function, incl. mechanisms facilitating dopamine synthesis and increasing dopamine release. Meta-analysis of PET-studies concluded: the primary dopaminergic abnormality in schizophrenia is elevated presynaptic function in the striatum, affecting dopamine synthesis capacity, baseline synaptic dopamine levels and dopamine release. Calipari & Ferris (2013) J Neurosci; Sulzer (2011) Neuron; Howes et al (2012) Arch Gen Psychiatry.

Cannabis use increases risk: why is the association less robust? Our finding is in line with previous studies showing that: Cannabis use increases risk of relapse in patients with schizophrenia – however, the association is not always robust. Why is the link not stronger? Importantly, our study, and previous studies, did not measure types of cannabis used: Accumulating evidence that main cannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD), have opposing effects on brain, cognition and behavior. While THC increases risk of psychosis, CBD has shown antipsychotic effects. Di Forti et al: daily use of high-potency, but not low-potency, cannabis is associated with a 5-fold risk of psychotic disorder in patients with first-episode psychosis. Rømer Thomsen et al (2017) Neurosci biobeh rev; Iseger & Bossong (2015) Schizophr Res; Di Forti (2016) Lancet Psychiatry.

Thc levels have increased markedly: implications for generalizability Since 2012 the increase in potency in cannabis resin has been dramatic Similar development has taken place in other European countries and in the US. In Denmark, mean THC levels in cannabis resin rose from 8% in 1992 to 29% in 2014. We studied the cohort from 2000 to 2013. New studies are needed to assess if the THC increase impacts risk of cannabis use. Fig 3. Mean THC and CBD content (%) 23% in 2016 THC 10% in 2009 CBD Dujourdy & Besacier (2017) Forensic sci int.

clinical implications The elevated risk related to amphetamine use indicates the importance of addressing amphetamine use in patients with a known history of schizophrenia. Despite a less robust association, use of cannabis in this group should call for caution: Other studies point to causal links between cannabis use and exacerbation of positive symptoms - particularly regarding high-potency cannabis. The fact that there has been a dramatic increase in potency of street cannabis underscores the need to address use of cannabis in this patient group. Di Forti et al (2016) Lancet Psychiatry; Rømer Thomsen et al (2017) Neurosci biobeh r; Dujourdy & Besacier (2017) Forensic sci int.

The study was done in close Collaboration with: birgitte thylstrup, michael m pedersen, mads uffe pedersen, erik simonsen & morten hesse